Hormonal contraceptive regimens in the perimenopause

Maturitas

Volumn 63, Issue 3, 2009, Pages 204-212

  Hardman, Sarah M R ^a   Gebbie, Ailsa E ^a  

^a NHS LOTHIAN   (United Kingdom)

Author keywords

Contraceptive; Hormonal; Perimenopause; Regimens

Indexed keywords

ANTIDEPRESSANT AGENT; CONTRACEPTIVE AGENT; DESOGESTREL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; ETONOGESTREL; GABAPENTIN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE;

BONE DENSITY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CONDOM; CONTRACEPTIVE DEVICE; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG MEGADOSE; ENDOMETRIUM CANCER; FERTILITY; HEALTH CARE PERSONNEL; HEART INFARCTION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; MENSTRUATION DISORDER; OVARY CANCER; PATIENT COMPLIANCE; PILL; QUALITY OF LIFE; REVIEW; STROKE; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VAGINA RING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; CONTRACEPTION; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; PERIMENOPAUSE; RISK ASSESSMENT;

EID: 67649592502     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.05.001     Document Type: Review

References (107)

1. Edouard L. Pill scare: communication conundrum. J Fam Plann Reprod Health Care 35 2 (2009) 121-122
2. Committee on the Safety of Medicines. Combined oral contraception and venous thromboembolism (1995), CSM, London
3. Guillebaud J. Advising women on which pill to take. BMJ 311 (1995) 1111-1112
4. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women; principal results from the WHI RCT. JAMA 288 3 (2002) 321-333
5. Beral V., et al. Breast cancer and HRT in the Million Women Study. Lancet 362 9382 (2003) 419-427
6. Dunson D.B., Columbo B., and Baird D.D. Changes with age in the level and duration of fertility in the menstrual cycle. Hum Reprod 17 5 (2002) 1399-1403
7. UK Office for National Statistics. Conceptions: age of woman at conception; 1991 Onwards (England and Wales residents): Population Trends 134 http://www.statistics.gov.uk/STATBASE/ssdataset.asp?vlnk=9558&More=Y .
8. Weisberg E., Bateson D., Read C., Estoesta J., and Lee C. Fertility control? Middle aged Australian women's retrospective reports of their pregnancies. Aust N Z J Public Health 32 4 (2008) 390-392
9. WHO e-reference http://www.who.int/reproductive-health/publications/mec/mec.pdf.
10. NICE guideline; Heavy Menstrual Bleeding: cg44 www.nice.org.uk/CG44niceguideline.
11. Lahteenmaki P., et al. Open randomised study of use of LNG-IUS as an alternative to hysterectomy. BMJ 316 7138 (1998) 1122-1126
12. MacLennan A., Lester S., and Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 4 1 (2001) 58-74
13. Archer D.F., Seidman L., Constantine G.D., Pickar J.H., and Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol (2008) [Epub ahead of print]
14. Brown J.N., and Wright B.R. Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy 29 1 (2009) 74-81
15. Low Doq T. Menopause: a review of botanical dietary supplements. Am J Med 118 Suppl. 12B (2005) 98-108
16. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women Health 15 1 (2006) 35-44
17. Beral V., Hermon C., Kay C., Hannaford P., Darby S., and Reeves G. Mortality associated with OC use: 25 year follow up of 46000 women from RCGP oral contraception study. BMJ 318 7176 (1999) 96-100
18. Hannaford P.C., Selvaraj S., Elliiott A.M., Angus A., Iversen L., and Lee A.J. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contracpetion study. BMJ 335 (2007) 651-654
19. Gallo M.F., et al. 20 mcg vs >20 mcg estrogen COC for contraception. Cochrane Database Syst Rev 8 4 (2008) CD003989
20. Akerlund M. Clinical experience of a COC with very low dose ethinyl estradiol. Acta Obstet Gynecol Scand Suppl 164 (1997) 63-65
21. van Vliet H.A. Triphasic vs monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 19 3 (2006) CD003553
22. Edelman A., et al. Continuous vs cyclic use of COC: a systematic cochrane review of randomised controlled trials. Hum Reprod 21 3 (2006) 573-578
23. Coffee A.L., et al. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 75 6 (2007) 444-449
24. O'Connell K., and Burkman R.T. The transdermal contraceptive patch-an updated review of the literature. Clin Obstet Gynecol 50 (2007) 918-926
25. Shimoni N., and Westhoff C. review of the vaginal contraceptive ring. J Fam Plann Reprod Health Care 34 (2008) 247-250
26. Lopez L.M., et al. Skin patch and ring versus COC for contraception. Cochrane Database Syst Rev 23 1 (2008) CD003552
27. Faculty of Sexual and Reproductive Healthcare. Evidence based guidelines on contraception for women aged over 40; 2005. www.ffprhc.org.uk/admin/uploads/contraceptionover40.pdf.
28. Hickey M., Higham J., and Fraser I.S. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 17 4 (2007) CD001895
29. Wong M.T., and Singh K. The combined oral contraceptive pill in women over age 40. Ann Acad Med Singapore 32 5 (2003) 624-631
30. Sulak P.J., Smith V., Coffee A., Witt I., Kuehl A.L., and Kuehl T.J. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a RCT. Obstet Gynecol 112 3 (2008) 563-571
31. Bruni V., Pontello V., Luisi S., and Petralgia F. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive ring Nuvaring. Eur J Obstet Gynecol Reprod Biol 139 1 (2008) 65-71
32. WHO. Cardiovascular disease and steroid hormone contraception: report of a WHO Scientific Group. Geneva, Switzerland: WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception; 1998. WHO Technical Report No. 877.
33. Farmer R.D., Lawrenson R.A., Todd J.C., Williams T.J., and MacRae K. Oral contraceptives and venous thromboembolic disease. Analyses of the UK GP presearch database and the UK Mediplus database. Hum Reprod Update 5 6 (1999) 688-706
34. Lindqvist P.G., Epstein E., and Olsson H. The relationship between lifestyle factors and VTE among women: a report from the MISS study. Br J Haematol 144 2 (2009) 234-240
35. Ageno W., Becattini C., Brighton T., Selby R., and Kamphuisen P.W. Circulation 117 January (1) (2008) 93-102
36. Martinez F., and Avecilla A. Combined hormonal contraception and VTE. Eur J Contracept Reprod Health Care 12 2 (2007) 97-106
37. Jick H., Kaye J.A., Vasilakis-Scarammozza C., and Jick S.S. Risk of VTE amongst users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 321 7270 (2000) 1190-1195
38. Creinin M.D., Lisman R., and Strickler R.C. Screening for factor V Leiden mutation before prescribing combination oral contraception. Fertil Steril 72 (1999) 646-651
39. Khader Y.S., Rice J., John L., and Abueita O. Oral contraceptive use and risk of MI: a meta-analysis 1966-2002. Contraception 68 1 (2003) 11-17
40. Progress in Human Reproduction Research 1998 no 46. Cardiovascular disease and steroid hormone contraceptives. UNDP/UNPA/WHO/World Bank Special programme of Research, Development and Research Training in Human Reproduction (HRP).
41. Croft P., and Hannaford P. RCGP OC Study. Risk factors for acute MI in women. BMJ 298 6674 (1989) 674
42. Suwikrom S., and Jaisamrarn U. Comparison of the metabolic effects of oral contraceptive and nonhormonal contraceptive use in women over 40 yrs. Contraception 71 3 (2005) 183-187
43. Tanis B.C., van den Bosch M.A., Kemmeren J.M., et al. Oral contraceptives and the risk of MI. N Engl J Med 345 25 (2001) 1787-1793
44. ESHRE Capri Workshop Group. Hormones and Cardiovascular health in women. Hum Reprod Update 12 5 (2006) 483-497
45. WHO Collaborative Study. Haemorrhagic stroke, overall stroke risk and COC: results of an international multicentre case-control study. Lancet 348 9026 (1996) 505-510
46. Gillum L.A., Mamidipudi S.K., and Johnston S.C. Ischaemic stroke risk with oral contraception: a meta analysis. JAMA 284 1 (2000) 72-78
47. Etminan M., Takkouche B., Isorna F.C., and Samii A. Risk of stroke in people with migraine. BMJ 330 January (7482) (2005) 63
48. National Cancer Institute Factsheet: Probability of Breast Cancer in American Women; 2006 http://www.cancernet.gov/cancertopics/factsheet/Detection/probability-br east-cancer.
49. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347 9017 (1996) 1713-1727
50. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. Oral contraceptives and breast cancer. N Engl J Med 346 26 (2002) 2025-2032
51. International collaboration of epidemiological studies of cervical cancer. Lancet 370 9599 (2007) 1609-1621
52. Moreno V., Bosch F.X., Munoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359 9132 (2002) 1085-1092
53. Cancer Research UK: UK cervical cancer incidence statistics http://info.cancerresearchuk.org/cancerstats/types/cervix/incidence/ (accessed April 2009).
54. Johnson J.V., Lowell J., Badger G.J., Rosing J., Tchaikovski S., and Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a RCT. Obstet Gynecol 111 2 Pt. 1 (2008) 278-284
55. Jick S.S., Kaye J.A., Russmann S., and Jick H. Risk of non fatal VTE in women using a contraceptive transdermal patch and oral contraceptives containing 35mcg EE and norgestimate. Contraception 73 3 (2006) 223-228
56. Cole J.A., Norman H., Doherty M., and Walker A.M. VTE, MI and stroke among transdermal contraceptive system users. Obstet Gynecol 109 2 Pt 1 (2007) 339-346
57. Grigoryan O.R., Grodnitskaya E.E., Andreeva E.N., Chebotnikova T.V., and Melnichenko G.A. Use of the Nuvaring hormone-releasing system in late reproductive age women with type 1 diabetes mellitus. Gynecol Endocrinol 24 2 (2008) 99-104
58. Elkind-Hirsch K.E., Darensbourg C., Ogden B., Ogden L.F., and Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 76 5 (2007) 348-356
59. Beral V., Doll R., Hermon C., Peto R., and Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet 371 9609 (2008) 303-314
60. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Study of the Centers for Disease Control. JAMA 257 6 (1987) 796-800
61. Kuohung W., Borgotta L., and Stubblefield P. Low dose oral contraceptives and BMD: an evidence-based analysis. Contraception 61 2 (2000) 77-82
62. Gambacciani M., Cappagli B., Lazzarini V., Ciaponi M., Fruzzetti F., and Genazzini A.R. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose OCP on BMD. Maturitas 54 2 (2006) 176-180
63. Cooper C., Hannaford P., Croft P., and Kay C.R. Oral contraceptive pill use and fractures in women: a prospective study. Bone 14 1 (1993) 41-45
64. Vessey M., Mant J., and Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 57 4 (1998) 231-235
65. Michaelsson K., Baron J.A., Farahmand B.Y., Persson I., and Ljunghall S. Oral contraceptive use and risk of hip fracture: a case control study. Lancet 353 9163 (1999) 1481-1484
66. Serup J., Bostofte E., Larsen S., and Westergaard J. Effectivity and acceptibility of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation. Acta Obstet Gynecol Scand 60 2 (1981) 203-206
67. Endrikat J., Parke S., Trummer D., Schmidt W., Duijkers I., and Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomised, open-label studies. Contraception 78 3 (2008) 218-225
68. Wiegratz I., Lee J.H., Kutschera E., Winkler U.H., and Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception 70 2 (2004) 97-106
69. Coelingh Bennink H.J., Skouby S., Bouchard P., and Holinka C.F. Ovulation inhibition by estetrol in an in vivo model. Contraception 77 3 (2008) 186-190
70. Milsom I., and Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 34 4 (2008) 237-246
71. Rice C.F., Killick S.R., Dieben T., and Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 mcg and levonorgestrel 30mcg daily. Hum Reprod 14 4 (1999) 982-985
72. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. UK Medical Eligibility Criteria for Contraceptive use; 2006. http://www.ffprhc.org.uk/admin/uploads/298_UKMEC_200506.pdf.
73. Kovacs G. Progestogen-only pills and bleeding disturbances. Hum Reprod 11 (1996) 20-23
74. Lethaby A., Irvine G., and Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 23 1 (2008) CD001016
75. Graesslin O., and Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 13 Suppl. 1 (2008) 4-12
76. Mansour D., Korver T., Marintcheva-Petrova M., and Fraser I.S. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 13 Suppl. 1 (2008) 13-28
77. Arias R.D., Jain J.K., Brucker C., Ross D., and Ray A. Changes in bleeding patterns with depo medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception 74 3 (2006) 234-238
78. Milsom I. The LNG-releasing intrauterine system as an alternative to hysterectomy in perimenopausal women. Contraception 75 6 Suppl. (2007) s152-s154
79. Hidalgo M., Bahamondes L., Perotti M., Diaz J., Dantas-Monteiro C., and Petta C. Bleeding patterns and clinical performance of the LNG IUS (Mirena) up to two years. Contraception 65 2 (2002) 129-132 PMID 11927115
80. Inki P. Longterm used of the LNG IUS. Contraception 75 June (6 Suppl.) (2007) s161-s166
81. Lete I., Obispo C., Izaquirre F., et al. The levonorgestrel IUS (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction. Eur J Contracept Reprod Health Care 13 3 (2008) 231-237
82. Jensen J.T., Nelson A.L., and Costales A.C. Subject and clinician experience with the levonorgestrel-releasing IUS. Contraception 77 1 (2008) 22-29
83. Kucuk T., and Ertan K. Continuous oral or IM medroxyprogesterone acetate versus the LNG IUS in the treatment of perimenopausal menorrhagia: a randomised, prospective, controlled clinical trial in female smokers. Clin Exp Obst Gynecol 35 1 (2008) 57-60
84. De Jonge E.T., Yigit R., Molenberghs G., Straetmans D., and Ombelet W. Predictors of oligoamenorrhoea at 1 year follow up in premenopausal women using a levonorgestrel releasing IUS. Contraception 76 2 (2007) 91-95
85. Lethaby A.E., Cooke I., and Rees M. Progesterone or progesterone-releasing IUS for heavy menstrual bleeding. Cochrane Database Syst Rev 19 4 (2005) CD002126
86. Heinemann L.A., Assmann A., DoMinh T., and Garbe E. Oral progestogen only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care 4 2 (1999) 67-73
87. Merkl-Feld G.S., Imthurn B., and Seifert B. Effects of the progestogen only contraceptive implant Implanon on cardiovascular risk factors. Clin Endocrinol (Oxf) 68 3 (2008) 355-360
88. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicentre, case-control study. Contraception 57 5 (1998) 315-324
89. Vasilakis C., Jick H., and del Mar Melero-Montes M. Risk of idiopathic VTE in users of progestogens alone. Lancet 354 9190 (1999) 1610-1611
90. Kayikcioglu F., Gunes M., Ozdeqirmenci O., and Haberal A. Effects of LNG-IUS on glucose and lipid metabolism: a 1 year follow up study. Contraception 73 5 (2006) 528-531
91. Editorial: contraceptive methods and breast cancer risk: an update. Contracept Rep 11 2 (2000) 9-11
92. Kumle M., Weiderpass E., Braaten T., Persson I., Adami H.O., and Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's lifestyle and health cohort study. Cancer Epidemiol Biomarkers Prev 11 November (11) (2002) 1375-1381
93. Backman T., Rauramo I., Jaakkola K., Inki P., et al. Use of the LNG-IUS and breast cancer. Obstet Gynecol 106 4 (2005) 813-817
94. Curtis K.M., and Martins S.L. Progestogen-only contraception and BMD: a systematic review. Contraception 73 5 (2006) 470-487
95. Beerthuizen R., van Beek A., Massai R., Makarainen L., Hout J., and Bennink H.C. BMD during longterm use of the progestogen contraceptive implant, Implanon compared to a non-hormonal method of contraception. Hum Reprod 15 1 (2000) 118-122
96. Shaarawy M., El-Mallah S.Y., Seoudi S., Hassan M., and Mohsen I.A. Effects of the longterm use of DMPA as hormonal contraceptive on BMD and biochemical markers of bone remodelling. Contraception 74 4 (2006) 297-302
97. Beksinska M.E., Smit J.A., Kleinschmidt I., Farley T.M., and Mbatha F. BMD in women aged 40-49 years using DMPA, norethisterone enenthate or COC for contraception. Contraception 71 3 (2005) 170-175
98. Clark M.K., Sowers M., Levy B., and Nichols S. BMD loss and recovery during 48 months in first time users of DMPA. Fertil Steril 86 5 (2006) 1466-1474
99. Kaunitz A.M., Arias R., and McClung M. Bone density recovery after DMPA injectable contraception use. Contraception 77 February (2) (2008) 67-76
100. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of injectable contraceptive DMPA on bone density in normal post-menopausal women. Clin Endocrinol 49 5 (1998) 615-618
101. Guilbert E.R., Brown J.P., Kaunitz A.M., et al. The use of DMPA in contraception and its potential impact on skeletal health. Contraception 79 3 (2009) 167-177
102. Gebbie A.E., Glasier A., and Sweeting V. Incidence of ovulation in perimenopausal women before and after hormone replacement therapy. Contraception 52 (1995) 221-222
103. Andersson K., and Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 97 (1990) 690-694
104. Lader D, Hopkins G, Office for National Statistics, Omnibus Survey Report no. 37, Contraception and Sexual Health; 2007-2008.
105. Volmink J.A., et al. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. Heart 80 (1998) 40-44
106. Rothwell P., Coull A., Silver L., et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366 (2005) 1773-1783
107. Scottish Cancer registry. Breast Cancer data. http://www.isdscotland.org/isd/1420.html.